GeneDx Holdings Corp

Latest Results (10.10.2025):

GeneDx Holdings Corp reported strong financial results for the second quarter of 2025, demonstrating significant revenue growth and improved profitability. The company achieved a substantial increase in exome and genome test revenues, expanded its gross margin, and raised its full-year revenue guidance, reflecting robust business performance and strategic advancements in the genetic testing market.

Revenue Growth

In the second quarter of 2025, GeneDx Holdings Corp reported revenues of $102.7 million, marking a 49% year-over-year increase. Exome and genome test revenue surged by 69% year-over-year, reaching $85.9 million, which now constitutes 41% of all tests compared to 31% in the same quarter last year.

Improved Gross Margin

The company expanded its adjusted gross margin to 71%, up from 62% in the second quarter of 2024. The total GAAP gross margin stood at 69%, reflecting enhanced cost management and increased revenue from high-margin genetic tests.

Enhanced Profitability

GeneDx achieved an adjusted net income of $15.0 million in the second quarter of 2025, a significant improvement from an adjusted net loss of $2.0 million in the second quarter of 2024. The GAAP net income was reported at $10.8 million.

Raised Full-Year Guidance

The company raised its full-year 2025 revenue guidance to between $400 and $415 million, anticipating 48% to 52% growth in exome and genome revenue. This upward revision underscores GeneDx's confidence in continued strong demand and market expansion.

Strategic Developments

GeneDx announced that the American Academy of Pediatrics now recommends exome and genome sequencing as first-line tests for children with global developmental delay or intellectual disability. Additionally, the company expanded its commercial focus to include providers treating children with inborn errors of immunity and accelerated coverage adoption by state Medicaid programs.

Innovation and Acquisition

The acquisition of Fabric Genomics positions GeneDx to deliver genomic insights globally through a hybrid centralized and decentralized model. Published studies highlight the company's leadership in leveraging artificial intelligence to enhance diagnostic yield and reduce time to diagnosis.